Clinical Trial

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 21, 2022 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will examine the effects of a six-month regimen of neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcomes, and exploratory data will be compared to a matched, retrospective cohort.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-12-10.
Status change: Not Yet Recruiting → Enrolling by Invitation 2022-09-15
Trial Details
NCT Number NCT05171335
Lead Sponsor The Methodist Hospital Research Institute
Collaborators: Eisai Inc.
Conditions Hepatocellular Carcinoma
Enrollment 50 participants
Start Date 2022-06-20
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2022-09-21